NEW YORK ( TheStreet) -- Cephalon Inc (Nasdaq: CEPH) hit a new 52-week high Thursday as it is currently trading at $81.15, above its previous 52-week high of $81.14 with two million shares traded as of 1:50 p.m. ET. Average volume has been 3.9 million shares over the past 30 days. Cephalon has a market cap of $6.3 billion and is part of the health care sector and drugs industry. Shares are up 31.1% year to date as of the close of trading on Wednesday. Cephalon, Inc., a biopharmaceutical company, engages in discovering and developing medicines for central nervous system disorders, pain, oncology, inflammatory disease, and regeneration worldwide. The company has a P/E ratio of 15.9, above the average drugs industry P/E ratio of 11.9 and below the S&P 500 P/E ratio of 17.7.
Practice your CEPH trading strategies and win cash in our stock game.
TheStreet Ratings rates Cephalon as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Cephalon Ratings Report. See all 52-week high stocks or get investment ideas from our investment research center.